3 Who Received AstraZeneca Vaccine In Hospital With "Unusual Symptoms"
Norway halted on Thursday the rollout of that vaccine, following a similar move by Denmark. Iceland later followed suit.
Three health workers in Norway who recently received the AstraZeneca vaccine against COVID-19 are being treated in hospital for bleeding, blood clots and a low count of blood platelets, Norwegian health authorities said on Saturday.
Norway halted on Thursday the rollout of that vaccine, following a similar move by Denmark. Iceland later followed suit.
"We do not know if the cases are linked to the vaccine," Sigurd Hortemo, a senior doctor at the Norwegian Medicines Agency told a news conference held jointly with the Norwegian Institute of Public Health.
All three individuals were under the age of 50.
The European medicine regulator EMA would investigate the three incidents, Hortemo added.
"They have very unusual symptoms: bleeding, blood clots and a low count of blood platelets," Steinar Madsen, Medical Director at the Norwegian Medicines Agency told broadcaster NRK.
"They are quite sick...We take this very seriously," he said, adding authorities had received notification of the cases on Saturday.
AstraZeneca was not immediately available for comment.
Before Denmark's and Norway's move, Austria stopped using a batch of AstraZeneca shots while investigating a death from coagulation disorders and an illness from a pulmonary embolism.
Still, EMA on Thursday said the vaccine's benefits outweighed its risks and could continue to be administered.
Europe is struggling to speed up a vaccine rollout after delivery delays from Pfizer and AstraZeneca, even as a spike in cases amid a more contagious virus variant has triggered fresh lockdowns in countries like Italy and France.
Norway halted on Thursday the rollout of that vaccine, following a similar move by Denmark. Iceland later followed suit.
"We do not know if the cases are linked to the vaccine," Sigurd Hortemo, a senior doctor at the Norwegian Medicines Agency told a news conference held jointly with the Norwegian Institute of Public Health.
All three individuals were under the age of 50.
The European medicine regulator EMA would investigate the three incidents, Hortemo added.
"They have very unusual symptoms: bleeding, blood clots and a low count of blood platelets," Steinar Madsen, Medical Director at the Norwegian Medicines Agency told broadcaster NRK.
"They are quite sick...We take this very seriously," he said, adding authorities had received notification of the cases on Saturday.
AstraZeneca was not immediately available for comment.
Before Denmark's and Norway's move, Austria stopped using a batch of AstraZeneca shots while investigating a death from coagulation disorders and an illness from a pulmonary embolism.
Still, EMA on Thursday said the vaccine's benefits outweighed its risks and could continue to be administered.
Europe is struggling to speed up a vaccine rollout after delivery delays from Pfizer and AstraZeneca, even as a spike in cases amid a more contagious virus variant has triggered fresh lockdowns in countries like Italy and France.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
